The clinical studies indicated<unk>  was well tolerated. The overall rate of adverse events was comparable between the two treatment groups (The CANVAS I and CANVAS II trials evaluated<unk>  monotherapy versus vancomycin plus aztreonam in adult subjects with complicated skin and skin structure infections caused by Gram-positive and Gram-negative bacteria.). The overall discontinuation rate for<unk> -treated subjects was 2.7% compared to a rate of 3.7% for the comparator group-treated subjects. The most common adverse reactions occurring in > 2% of subjects receiving<unk>  in the pooled phase-III clinical trials were diarrhea, nausea, and rash.:
Ceftaroline fosamil
Imipenem
Amikacin
Imipenem/cilastatin/relebactam
Rifampicin
Secnidazole
Doxycycline
Doripenem